New drug cocktail shows promise for hard-to-treat lymphoma
NCT ID NCT07418190
First seen Feb 23, 2026 · Last updated May 16, 2026 · Updated 14 times
Summary
This study tests a combination of four drugs (zanubrutinib, rituximab, lenalidomide, and tislelizumab) in 33 adults with follicular lymphoma that has returned or not responded to at least two prior treatments. The goal is to see how well the combo shrinks or eliminates tumors after six 21-day cycles. Those who respond will continue on two of the drugs for up to a year to keep the cancer in check.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Jiangsu Province Hospital
RECRUITINGNanjing, Jiangsu, 210000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.